Triple-negative breast cancers (TNBCs) lack the expression of estrogen receptor (ERα), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2) and are the major cause of BC mortality due to aggressive invasive and metastatic potential; lack of suitable molecular treatment targets; and resistance to conventional chemotherapeutic agents [3,4]. The gene discussed is PGR; the disease is triple-negative breast carcinoma.